recommendations to optimise reporting of epidemiological studies on
antimicrobial resistance and informing improvement in antimicrobial
stewardship by Tacconelli, Evelina et al.
STROBE-AMS: recommendations to
optimise reporting of epidemiological
studies on antimicrobial resistance
and informing improvement in
antimicrobial stewardship
Evelina Tacconelli,1,2 Maria A Cataldo,3 M Paul,4 L Leibovici,5 Jan Kluytmans,6
Wiebke Schröder,1,2 Federico Foschi,1,2 Giulia De Angelis,3 Chiara De Waure,7
Chiara Cadeddu,7 Nico T Mutters,8 Petra Gastmeier,9 Barry Cookson10
To cite: Tacconelli E,












and additional material is




Received 30 September 2015
Revised 3 December 2015
Accepted 18 December 2015







Objectives: To explore the accuracy of application of
the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) tool in
epidemiological studies focused on the evaluation of
the role of antibiotics in selecting resistance, and to
derive and test an extension of STROBE to improve the
suitability of the tool in evaluating the quality of
reporting in these area.
Methods: A three-step study was performed. First, a
systematic review of the literature analysing the
association between antimicrobial exposure and
acquisition of methicillin-resistant Staphylococcus
aureus and/or multidrug-resistant Acinetobacter
baumannii was performed. Second, articles were
reviewed according to the STROBE checklist for
epidemiological studies. Third, a set of potential new
items focused on antimicrobial-resistance quality
indicators was derived through an expert two-round
RAND-modified Delphi procedure and tested on the
articles selected through the literature review.
Results: The literature search identified 78 studies.
Overall, the quality of reporting appeared to be poor
in most areas. Five STROBE items, comprising
statistical analysis and study objectives, were
satisfactory in <25% of the studies. Informative
abstract, reporting of bias, control of confounding,
generalisability and description of study size were
missing in more than half the articles. A set of 21
new items was developed and tested. The new
items focused particularly on the study setting,
antimicrobial usage indicators, and patients
epidemiological and clinical characteristics. The
performance of the new items in included studies
was very low (<25%).
Conclusions: Our paper reveals that reporting in
epidemiological papers analysing the association
between antimicrobial usage and development of
resistance is poor. The implementation of the newly
developed STROBE for antimicrobial stewardship
(AMS) tool should enhance appropriate study design
and reporting, and therefore contribute to the
improvement of evidence to be used for AMS
programme development and assessment.
INTRODUCTION
The rate of infections caused by antimicrobial-
resistant microorganisms is seen increasingly
by the public and healthcare inspection orga-
nisations as an indicator of quality of health-
care and patient safety.1 Several studies have
explored risk factors associated with infection
or colonisation due to antimicrobial-resistant
microorganisms.2 3 Among them, antimicro-
bial exposure is a well-known risk factor for
Strength and limitations of this study
▪ This study developed a revised version of
Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) to increase
appropriateness of reporting for epidemiological
studies focused on the link between
antimicrobial-resistant bacteria and antibiotic
usage.
▪ STROBE for antimicrobial stewardship
(STROBE-AMS) was developed through a
2-round Delphi experts approach. The final set
included 21 new variables and four areas were
graded as the most relevant: definition of infec-
tion and/or colonisation; setting; antibiotic usage
at patient’s and hospital’s level; molecular resist-
ance mechanisms; and infection control.
▪ The STROBE-AMS application was tested only in
epidemiological studies on methicillin-resistant
Staphylococcus aureus and multidrug-resistant
Acinetobacter baumannii. Since the postdevelop-
ment test was performed only for observational
reports, no specific bias was introduced.
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subsequent infections due to methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin-resistant
enterococci (VRE) and multidrug-resistant (MDR)
Gram-negative bacteria.4–6 Antimicrobial stewardship
(AMS), included in a multifaceted approach, represents
an essential tool to combat the spread of resistance in
the healthcare setting.7 8 An effective AMS programme
should include the appropriate choice of empirical
therapy (including decision on no antimicrobial treat-
ment) as well as duration and dosage of the drug in
order to provide the best outcome for the patient, to
reduce adverse effects, and to prevent and control the
rate of antimicrobial resistance.9 As with intervention
measures, AMS should be based on evidence. However,
although randomised controlled trials (RCTs) are con-
sidered to be the gold standard of epidemiological
research, analyses of risk factors for antimicrobial-
resistant infections, especially those in which we can
intervene, are usually not tested by RCTs, and rely
mainly on observational studies. The major limitations
of epidemiological studies on antimicrobial-resistant
infections are the retrospective design, poor controlling
for confounding factors (ie, duration and dosage of anti-
biotics, knowledge of carrier status, combination and
sequential antibiotic therapy) and heterogeneity in
several deﬁnitions (ie, deﬁnition of infection and of
antimicrobial-resistant microorganisms, time-at-risk
period for previous antimicrobial exposure, selection of
control group).10–13 A further limitation affects external
validity, since prevalence of resistance changes in differ-
ent locations and in time. In an era of increasing anti-
microbial resistance, reducing these ﬂaws and increasing
appropriate reporting is critical to the application of
ﬁndings to AMS programmes.
The ‘Strengthening the Reporting of Observational
Studies in Epidemiology’ (STROBE) was an initiative to
improve the quality of reporting evidence.14 It aimed to
provide useful guidance by establishing a checklist con-
sisting of 22 items for the transparent and complete
publication of observational studies, facilitating their
critical evaluation.14 Recently, an extension of the
STROBE statement (STROME-ID) established recom-
mendations to support good scientiﬁc reporting of
molecular epidemiological studies.15 However, the pecu-
liarity of the epidemiology of antimicrobial-resistant
infections being strongly connected to patients’
characteristics as well as to different settings (hospital,
community and healthcare centres) as well as surveil-
lance methods of antibiotic usage (ie, deﬁned daily
dose or packets or prescriptions) cannot be properly
covered through the items currently included in
STROBE.
Therefore, we performed a study with two main
objectives: (1) to explore the accuracy of application of
STROBE in epidemiological studies focused on the link
between antibiotics usage and development of resist-
ance; and (2) to derive and test an extension of
STROBE that could improve the suitability of the tool
in evaluating the quality of reporting of epidemiological
studies in this area. Studies addressing MRSA and the
MDR-Acinetobacter baumannii group were selected for
the frequency with which they have been used




There were three-steps to the study design. First, to
explore the STROBE application, we searched the litera-
ture (1976–2013) for articles analysing the association
between antimicrobial exposure, and acquisition of
MRSA and/or MDR-A. baumannii. Second, all the arti-
cles were reviewed according to the STROBE checklist.14
Third, a set of potential new items focused on
antimicrobial-resistance quality indicators for proper
reporting was derived through a two-round RAND-modi-
ﬁed Delphi procedure, involving experts in the ﬁeld of
antimicrobial prescribing.17 The extension of STROBE
for AMS (STROBE-AMS) was then tested on the articles
selected in the ﬁrst study step.
Selection of articles
Published human studies concerning the role of previ-
ous antimicrobial therapy as a risk factor for developing
MRSA and MDR-A. baumannii colonisation or infection
in hospitalised patients were identiﬁed through compu-
terised literature searches using MEDLINE (National
Library of Medicine, Bethesda, Maryland, USA) and
EMBASE (Excerpta Medica Database), and by reviewing
the references of the retrieved articles. Index search
terms included the following Medical Subject Headings:
‘risk factors’, ‘resistance’, ‘antimicrobial therapy’,
‘Acinetobacter’, ‘outbreak’, ‘Staphylococcus aureus’ and
‘methicillin-resistant’. The search was carried out with
no language restriction and followed PRISMA
(Preferred Reporting Items for Systematic reviews and
Meta-Analyses) guidelines. Studies were considered eli-
gible if they included adult patients (>16 years old) and
presented data pertaining to the relationship between
antimicrobial use and the development of MRSA or
MDR-A. baumannii colonisation or infection. Authors
were contacted for missing information.
Data extraction
Data extraction was performed by four independent
researchers in two centres. This process involved infec-
tious disease specialists as well as epidemiologists. In
case of disagreement among the reviewers, a senior
reviewer was consulted. Reviews, letters, editorials and
case reports were excluded. Data extraction included
also the impact factor (IF) of the journal (2013 Journal
Citation Report, Thomson Institute for Scientiﬁc
Information), which is a measure of average citation fre-
quency for all the articles over a given period of time.
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Reporting assessment
The assessment of the quality of reporting was per-
formed according to the STROBE statement.14 Data
from each study were entered into standardised forms,
veriﬁed for consistency and accuracy, and then entered
into a computerised database. Entries for each item of
the STROBE statement were categorised as ‘Yes’, if they
were completely in agreement with the STROBE state-
ment explanation and elaboration documentation, ‘No’,
if this was not satisﬁed, and ‘Partly’, if evident only in
part of the text. Absolute and relative frequencies were
used to describe the results of these judgments of quality
of reporting according to the STROBE statement.
New items development
The new items development was carried out through a
two-round Delphi approach. A list of experts in the ﬁeld of
antimicrobial prescribing was collated from the network of
the European Society of Infectious Diseases and Clinical
Microbiology (ESCMID) and the Impact of Speciﬁc
Antibiotic Therapies on the prevalence of hUman host
ResisteNt bacteria (SATURN) Project on antimicrobial
usage and selection of resistance in hospitalised patients
(EU-7th FP7-241796). To develop a ﬁrst set of quality indi-
cators, the literature was reviewed to deﬁne the major lim-
itations of current research on the association between
antimicrobial usage and antimicrobial resistance,11 18 19
and a ﬁrst set of indicators, developed from the authors,
was sent out in December 2013. Respondents were asked
to rate each new item against two continuous 1–9 integer
scales and provide their comments. The second round was
performed in May 2014, according to the same indications.
Ethic consent was not required because no patient data
were used and the study was based on literature review.
Test of the new items
The new developed items were then applied to the papers
selected for the systematic review. The same reporting
assessment used for the STROBE evaluation was applied.
Statistical analysis
Scores were analysed using a non-parametric test
(Fischer’s test). Analysis was performed with STATA
V.12.1 (Stata Corporation, Texas, USA).
Table 1 STROBE item checklist for 78 epidemiological studies analysing antimicrobial usage and development of
colonisation/infections due to MRSA and MDR-Acinetobacter baumannii
Level of
satisfaction STROBE statement number Section
<25% of studies 3. State specific objectives, including any prespecified hypotheses. Introduction
9. Describe any efforts to address potential sources of bias
10. Explain how the study size was arrived at
11. Explain how quantitative variables were handled
Methods
17. Report other analyses performed—eg, analyses of subgroups Results
≥25% to <50%
of studies
1a. Indicate the study design with a commonly used term in the title or the abstract
1b. Provide an informative and balanced summary in the abstract
Title and Abstract
19. Discuss limitations of the study, taking into account sources of potential bias or
imprecision
21. Discuss the generalisability
Discussion
22. Give the source of funding Funding
≥50% to <75%
of studies
2. Explain the scientific background and rationale for the investigation being reported. Introduction
4. Present key elements of study design early in the paper
7. Clearly define all outcomes, exposures, predictors, potential confounders, and
effect modifiers
8. For each variable of interest, give sources of data and details of methods of
assessment
Methods
13. Report the numbers of individuals at each stage and reason for non-participation
16. Give unadjusted estimates and, if applicable, confounder-adjusted estimates.
Make clear which counfounders were adjusted for and why they were included
Results
≥75% of studies 5. Describe the setting, locations and relevant dates
6. Description of participants—eligibility criteria, sources and methods
12. Describe all statistical methods, including those used to control for confounding.
Explain how missing data, lost to follow up and sensitivity analyses were addressed
Methods
14. Give the characteristics of study participants
15. Report outcome data
Results
18. Summarise key results with reference to study objectives
20. Give a cautious overall interpretation of results
Discussion
Bold typeface indicates main variables included in the STROBE tool.
MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; STROBE, Strengthening the Reporting of Observational
Studies in Epidemiology.
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RESULTS
Identification of relevant articles
The search identiﬁed 1008 potentially relevant studies;
311 were excluded because they were reviews, case
reports or letters; 233 were excluded because they did
not investigate previous antibiotic therapy. Among the
remaining 464, 386 articles were excluded because they
did not analyse the relationship between antibiotic
usage and development of resistance, were duplicates, or
their authors could not provide missing information.
Overall, 78 studies (57 on MRSA and 21 on
MDR-Acinetobacter) fulﬁlled inclusion criteria for the
association between antimicrobial usage and antimicro-
bial resistance: 39 (51%) case–control, 28 (35%) cohort
and 11 (14%) cross-sectional studies. The list of reviewed
articles and the ﬂow chart are reported in online supple-
mentary annex 1—ﬁgure 1 and table 1.
Reporting assessment
The results of the assessment of quality of reporting
through the STROBE statement of these 78 studies are
shown in table 1. Overall, the quality of reporting
appeared to be poor in most areas. Best performing
areas of the STROBE tool were seven items including the
description of setting, participants and generic review of
statistical methods that were well satisﬁed in >75% of the
studies. However, ﬁve items, comprising statistical details
for the analysis of quantitative variables, subgroup ana-
lysis, sample size calculation, addressing potential sources
of biases and, most notably, the description of main study
objectives, were satisfactory in <25% of the studies.
Table 2 describes the association between the value of
the IF and the grade of satisfaction of the STROBE state-
ment’s items. Informative abstract, explanation of objec-
tives, reporting of bias, statistical methods, control of
confounding, generalisability, deﬁnition of quantitative
variables, giving of estimates and description of study
size, were missing or incomplete in more than half the
articles published in 13 journals with IF greater than
four. The cut-off of four was selected based on the IF
median distribution. There was no association between
type of journal (general medicine vs clinical infectious
diseases and microbiology-dedicated journal) and year
of study publication (before and after 2007, when the
STROBE tool was introduced).
Development of new items
In the ﬁrst round, 16 new items were sent to the experts.
No indicators were discarded between rounds and ﬁve
new items were added. In the second round, participants
were provided with the frequency of distribution of
scores and qualitative comments. The ﬁnal set included
21 new variables, presented in table 3. The main new
items referred to the description of the study setting and
participants. In particular, the following four areas were
graded as the most relevant for studies reporting on
antimicrobial usage and resistance development: deﬁn-
ition of infection and/or colonisation, and evidence of
robustness of the new deﬁnition (if not a validated refer-
ence); deﬁnition of setting (epidemic or endemic); def-
inition of antibiotic usage at patient’s level including
type, dosage, duration, route of administration and com-
binations; description of antimicrobial formulary at the
hospital level and measurement of antibiotic usage
(deﬁned as daily dosage, packet daily dosage, treat-
ments, units), deﬁnition of how antibiotic consumption
data were obtained (pharmacy, patients’ charts, etc) and
if it was actually used or purchased/dispensed. The
remaining three items focused on infection control mea-
sures applied at the study location: deﬁnition of resist-
ance, cross-resistance and molecular resistance
Table 2 Association between satisfaction of the STROBE











Study design reported in
title/abstract
7 (54) 28 (53) 2 (17)
Informative abstract included 5 (38) 22 (42) 2 (17)
Background/rationale
explained
10 (77) 40 (75) 3 (25)
Objectives explained 4 (31) 11 (21) 2 (17)
Key elements of study design
defined
10 (77) 28 (53) 3 (25)
Hospital/community setting
explained
13 (100) 44 (83) 8 (67)
Eligibility criteria defined 12 (92) 47 (89) 7 (58)
Epidemiological variables
described
10 (77) 35 (66) 6 (50)
Data sources/measurement
defined
9 (69) 34 (64) 4 (33)
Analysis of study bias
included
1 (8) 0 0
Justification of study sample
size reported
1 (8) 4 (8) 0




5 (38)* 5 (9)* 0
Number of participants
reported
9 (69) 34 (64) 5 (42)
Characteristics of participants
reported
13 (100) 52 (98) 9 (75)
Outcome data defined 13 (100) 51 (96) 8 (67)
Unadjusted and adjusted
estimates given
6 (46) 18 (34) 2 (17)
Key results summarised 13 (100) 50 (94) 8 (67)
Limitations of the study
considered
8 (62) 27 (51) 2 (17)
Interpretation of results
provided
13 (100) 45 (85) 7 (58)
Generalisability of study
reported
6 (46) 20 (38) 4 (33)
*p≤0.05 based on two-sided Fisher’s exact test comparing the
proportions among articles with journal IF>4 vs IF≤4.
IF, impact factor; STROBE, Strengthening the Reporting of
Observational Studies in Epidemiology.
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Table 3 New checklist items proposed to be included in the STROBE statement for deepening the assessment of
epidemiological studies analysing the impact of antimicrobial usage on the development of antimicrobial-resistant infections
Item
Item




2 Explain the scientific background and
rationale for the investigation being
reported
2.1 Report previous clinical in vivo and in vitro
studies
Objectives 3 State specific objectives, including any
prespecified hypotheses
Methods
Setting 5 Describe the setting, locations, relevant
dates, including periods of recruitment,
exposure, follow-up and data collection
5.1 Describe if setting is epidemic or endemic
(high, low, medium) for the study outcome
5.2 Specify type of hospital or unit and
characteristics of population served by the
healthcare setting
5.3 Describe antimicrobial formulary in use at
the study location related to the analysed
antibiotics
5.4 Describe infection control measures
dedicated to the target resistant bacteria applied at
the study location
Participants 6 (a) Cohort study—Give the eligibility
criteria, the sources and methods of
selection of participants. Describe
methods of follow-up
6.1 Define unit analysed (person, department or
other)
Case–control study—Give the eligibility
criteria, the sources, methods of case
ascertainment and control selection. Give
the rationale for the choice of cases and
controls
Cross-sectional study—Give the eligibility
criteria, the sources and methods of
selection of participants
(b) Cohort study—For matched studies,
give matching criteria, the number of
exposed and unexposed
Case–control study—For matched
studies, give matching criteria and the
number of controls per case
6.2 Provide reasons (epidemiological and clinical)
for choosing matching criteria
Variables 7 Clearly define all outcomes, exposures,
predictors, potential confounders and
effect modifiers. Give diagnostic criteria,
if applicable
7.1 Specify antimicrobial usage according to:
type, dosage, duration and route of
administration
7.2 Provide information using defined daily
dosages (DDDs) and, in addition, other definitions
closer to local reality (packages, prescriptions).
Provide justification for the measurement
presented
7.3 Address antimicrobial combinations
7.4 Explain rationale for grouping of
antimicrobials
7.5 Define time at risk for antimicrobial exposure
and for resistance development
7.6 Include description of potential confounders
(other than epidemiological variables)
7.7 Provide definition of resistance, multidrug
resistance, including pattern of co-resistance;
whether studies performed to identify location or
resistance eg, plasmid, chromosome, integron,
transposon
Continued
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mechanisms, for example, plasmids, chromosomes, inte-
grons, transposons; and statistical methods including
controlling for confounders, rationale for grouping of
antimicrobials and time at risk for antimicrobial expos-
ure. Among the confounders, items reporting on previ-
ous stay in long term care facilities, nursing home and
other hospitals, were added.
Test of new items
The performance of reviewed articles to the new items
was very poor. Overall, the new items were satisﬁed in
<25% of the papers reviewed (item 5.3, 6.2, 7.1–4, 8, 11,
17 and 21).
DISCUSSION
With increasing reporting of antibiotic-resistant infec-
tions worldwide, epidemiological investigations on risk
factors for resistance require rather special attention
regarding designing and reporting in order to maximise
their ability to inform AMS programmes. Our paper
reveals that current reporting in epidemiological studies
focusing on the association between antibiotic usage
and development of resistance is very poor. Although
some items including the description of setting and
generic review of statistical methods were well satisﬁed in
>75% of the studies, more than half the 22 domains
included in the STROBE checklist were not satisﬁed in
the majority of studies analysing the role of antibiotics in
selecting MRSA and MDR-A. baumannii.
The major consequence of this inaccuracy is that a sig-
niﬁcant part of the evidence contributing to the devel-
opment of AMS programmes is currently of a very low
level. Improvement of reporting could be achieved at
two different levels: on the one side, it is essential to




number STROBE recommendation STROBE-AMS new items
7.8 Definition of infection and/or colonisation. If
not a validated reference, provide evidence of
robustness of the new definition
Data sources/
measurement
8 For each variable of interest, give
sources of data and details of methods of
assessment (measurement). Describe
comparability of assessment methods if
there is more than one group
8.1 Describe how antimicrobial consumption
data were obtained (pharmacy, patients’ charts,




11 Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen,
and why
11.1 Provide subgroup analyses for
immunocompromised, surgical/medical patients




14 (a) Give characteristics of study
participants (eg, demographic, clinical,
social) and information on exposures and
potential confounders
14.1 Specify among the exposure: previous stay
in long-term care facilities, nursing home and
other healthcare settings
(b) Indicate number of participants with
missing data for each variable of interest
(c) Cohort study—Summarise follow-up
time (eg, average and total amount)
Other analyses 17 Report other analyses performed—eg,
analyses of subgroups and interactions,
and sensitivity analyses
17.1 Report subgroup analysis by type of
patients and type of microorganism, if applicable
Discussion
Limitations 19 Discuss limitations of the study, taking
into account sources of potential bias or
imprecision. Discuss both direction and
magnitude of any potential bias
19.1 Provide description of sources of selection
bias, including infection control measures, audit
and confounding
Generalisability 21 Discuss the generalisability (external
validity) of the study results
21.1 Discuss study setting, type of hospital,
local epidemiology for the generalisability
Other information
Funding 22 Give the source of funding, the role of the
funders for the present study and, if
applicable, for the original study on which
the present article is based
Bold typeface indicates main variables included in the STROBE tool.
STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; STROBE-AMS, STROBE for antimicrobial stewardship.
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the importance of the appropriate reporting for epi-
demiological studies on antimicrobial resistance, and on
the other, availability of items speciﬁcally developed for
this ﬁeld could play a pivotal role, and increase feasibil-
ity and implementation. The new items developed by a
group of experts through a Delphi approach, which
combined evidence and expert opinion, mainly focuses
on the methods section and includes speciﬁc epidemio-
logical items (ie, deﬁnition of the epidemiological
setting in terms of endemicity or epidemicity) as well as
a set deﬁnitions for antimicrobial usage (ie, local formu-
lary, antibiotic measurements, presence or absence of
any AMS, etc). To further underline the innovation of
the items and the importance of introducing the new
STROBE-AMS, our results showed that the new items
were not reported in more than two-thirds of 78 already
published studies.
Interestingly, although a signiﬁcant correlation was
observed between the IF of the journal and satisfactory
compliance with the STROBE statement criteria, there
were very important areas such as an informative
abstract, explanation of objectives, reporting of statistical
methods and generalisability, that were missing or
incomplete in >50% of articles published even in
higher quality journals with IF factors >4. This result
underlines the need for involvement of major scientiﬁc
journals on clinical infectious diseases in a re-evaluation
process concerning the review process of such papers.
Indeed, RCTs are not accepted for publication in high-
ranked journals if they do not comply with the
CONSORT guidelines (Consolidated Standards for
Reporting Trials).20 Similarly, systematic reviews and
meta-analyses need to comply with the PRISMA guide-
lines.21 We would advocate that, for observational trials
on antibiotic-resistant infections, where there is a
greater potential for bias, this adaptation of the
STROBE tool must be an essential review requirement,
signiﬁcantly contributing to the global efforts to combat
the spread of antimicrobial-resistant microorganisms
with improvement of the quality of evidence of the
reports. Implicit in this requirement is that the studies
will have had to consider these checklists at the design
stage as well.
Our study has limitations. The analysis of STROBE
application in the ﬁeld of antimicrobial-resistant micro-
organisms was limited to epidemiological studies on
MRSA and MDR-A. baumannii. These microorganisms
were selected as their occurrence is very common, the
majority of published epidemiological studies are
focused on these bacteria, and their prevention and
control are important potential indicators of the success,
or otherwise, of healthcare associated interventions. The
testing of the new items was performed on the same
group of articles tested for satisfying the STROBE.
However, we believe that, since the postdevelopment test
was performed only for observational reports, no speciﬁc
bias was introduced. Generalisability of our study applies
therefore only to epidemiological studies exploring the
association between previous antibiotic therapy and
development of infection and/or colonisation due to
antimicrobial-resistant strains.
Our study has shown, through an expert’s Delphi
approach, that the current version of the STROBE tool
does not describe all the components considered essen-
tial to deﬁne the association between antibiotic usage
and resistance. That these studies should be conducted
and reported effectively has become an imperative,
given the global threat imposed by antimicrobial-
resistant microorganisms, for future effective therap-
ies.1 18 19 Increasing proper reporting will reduce het-
erogeneity between papers, and assist in the evaluation
of the evidence through systematic reviews and peer
reviewing for journal and grant proposals. The imple-
mentation of the STROBE-AMS will also impact on
other aspects of antimicrobial-resistant research, includ-
ing study design, extraction of data and generalisability
of results. We do believe that the introduction of
STROBE-AMS will increase the quality of available evi-
dence to policymakers, relevant healthcare workers and
the research community, and ultimately ensure that
there are sustained improvements to AMS throughout
the world.
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